Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)

Next Previous
X
Search
Trial Profile

A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; BI 836858 (Primary) ; Cytarabine (Primary) ; Daunorubicin (Primary) ; Decitabine (Primary) ; Dubermatinib (Primary) ; Enasidenib (Primary) ; Entospletinib (Primary) ; Gilteritinib (Primary) ; Ivosidenib (Primary) ; Lomonitinib (Primary) ; Pevonedistat (Primary) ; Revumenib (Primary) ; Samalizumab (Primary) ; SRA 515 (Primary) ; Venetoclax (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Biomarker; Therapeutic Use
  • Acronyms The Beat AML Trial

    • Most Recent Events

    • 14 Jun 2024 According to a Syndax Pharmaceuticals media release, the positive updated data from this trial presented at the European Hematology Association (EHA) 2024 Congress.
    • 14 Jun 2024 Results presented in Syndax Pharmaceuticals media release.
    • 11 Jun 2024 According to an Eilean Therapeutics media release, the company has joined joined The Leukemia & Lymphoma Society (LLS) in the collaborative Beat AML Master Clinical Trial. Lomonitinib (ZE46-0134) has been selected for a new trial arm for patients with FLT3 mutated relapsed/refractory (R/R) acute myeloid leukemia (AML).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top